NetScientific : PDS equity issue and related party transaction

Regulatory Story
Go to market news section
NetScientific PLC - NSCI PDS equity issue and related party transaction Released 11:07 12-Feb-2020

RNS Number : 7809C

NetScientific PLC

12 February 2020

NetScientific plc

('NetScientific' or the 'Company')

PDS Biotechnology equity issue and related party transaction

NetScientific plc ('NetScientific', AIM:NSCI) the transatlantic healthcare IP commercialisation group, announces that its portfolio company PDS Biotechnology Corporation ('PDS') (Nasdaq: PDSB) has today announced an issue of 9,230,770 new shares of common stock to raise gross proceeds of approximately US$12 million ('New Issue'), before deducting underwriting discounts, commissions and other offering expenses. The offering is expected to close on Friday, February 14, 2020, subject to customary closing conditions.

NetScientific currently owns 542,000 shares of PDS' common stock, representing approximately 10.28% of its undiluted share capital. The Board of NetScientific believes that PDS has strong prospects. It has therefore agreed to subscribe US$650,000 for 500,000 shares of common stock in the New Issue. Upon completion of the New Issue, NetScientific expects to own 1,042,000 shares of PDS' common stock, representing approximately7.18% of the undiluted share capital.

NetScientific has cash to fund this investment, however for prudent financial management is entering into an 18 month secured £500,000 loan facility with Beckman Group. The facility, which incurs interest of 10.0% pa on drawn amounts and 3.0% pa on undrawn amounts and has an arrangement fee of 1%, can be extended by mutual agreement for an additional 6 months, and is secured on the whole of NetScientific's interest in PDS.

As Beckman Group is associated with M A Lawson, who is interested in 29.98 % of NetScientific's issued share capital, the secured loan facility represents a related party transaction in accordance with Rule 13 of the AIM Rules for Companies. The Directors of NetScientific consider, having consulted the Company's nominated adviser, that the terms of the facility are fair and reasonable insofar as its shareholders are concerned.

For more information, please contact:

NetScientific Tel: [phone]

Ian Postlethwaite, CEO and CFO

WH Ireland (NOMAD and Broker) Tel: [phone]

Chris Fielding / Darshan Patel

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

MSCSFLFFEESSESE

Close

London Stock Exchange plc is not responsible for and does not check content on this Website. Website users are responsible for checking content. Any news item (including any prospectus) which is addressed solely to the persons and countries specified therein should not be relied upon other than by such persons and/or outside the specified countries. Terms and conditions, including restrictions on use and distribution apply.

©2014London Stock Exchange plc. All rights reserved

PDS equity issue and related party transaction - RNS